整合素连接激酶在子宫内膜癌组织中的表达及其对细胞迁移和侵袭能力的影响

doi:10.13481/j.1671-587x.20200518

摘要/Abstract

摘要： 目的：观察子宫内膜癌患者癌组织中整合素连接激酶（ILK）的表达水平，通过体外细胞实验探讨其对子宫内膜癌细胞迁移和侵袭能力的影响，并阐明其作用机制。方法：采用免疫组织化学SP法检测29例子宫内膜癌患者癌组织和癌旁组织细胞中ILK阳性表达率。分别将ILK siRNA和siRNA control转染至子宫内膜癌HEC-1B细胞作为干扰组和空载组，以不作处理的细胞作为对照组；采用Western blotting法检测HEC-1B细胞中ILK、蛋白激酶B（Akt）、磷酸化Akt（p-Akt）、糖原合成酶激酶3β（GSK-3β）和磷酸化GSK-3β（p-GSK-3β）蛋白表达水平，细胞划痕实验检测细胞迁移距离，Transwell小室法检测侵袭细胞数。结果：29例子宫内膜癌患者癌组织中ILK阳性表达率为79.3%，癌旁组织中ILK阳性表达率为10.3%，子宫内膜癌组织中ILK阳性表达率明显高于癌旁组织（P<0.05）。与对照组和空载组比较，干扰组HEC-1B细胞中ILK、p-Akt和p-GSK-3β蛋白表达水平明显降低（P<0.05），Akt和GSK-3β蛋白表达水平差异无统计学意义（P>0.05）；细胞划痕实验，与对照组和空载组比较，干扰组HEC-1B细胞迁移距离明显缩短（P<0.05），侵袭细胞数明显减少（P<0.05）。结论：ILK在子宫内膜癌组织中呈高水平表达，干扰ILK表达能够降低子宫内膜癌细胞的迁移和侵袭能力，其作用机制可能与其抑制Akt和GSK-3β蛋白磷酸化有关。

关键词: 整合素连接激酶, 子宫内膜癌, 细胞迁移, 细胞侵袭

Abstract: Objective: To observe the expression levels of integrin-linked kinase (ILK) in cancer tissue of the patients with endometrial carcinoma and explore its effects on the migration and invasion abilities of endometrial carcinoma cells through in vitro cell experiment, and to elucidate the mechanism. Methods: Immunohistochemical SP method was used to detect the positive expression rates of ILK in cancer tissue and adjacent tissue in 29 patients with endometrial carcinoma. ILK siRNA and siRNA control were respectively transfected into the endometrial carcinoma HEC-1B cells as interference group and empty vector group, while the untreated cells were used as control group. Western blotting method was used to detect the expression levels of ILK, protein kinase B(Akt),phosphorylated Akt(p-Akt), glycogen synthase kinase-3β(GSK-3β) and phosphorylated GSK-3β(p-GSK-3β) in the HEC-1B cells. Cell scratch test was used to detect the cell migration distance. Transwell chamber method was used to detect the number of invasion cells. Results: The positive expression rates of ILK in 29 cases of endometrial carcinoma and adjacent tissues were 79.3% and 10.3%,respectively;the expression level of ILK in endometrial carcinoma tissue was significantly higher than that in adjacent tissue (χ²=27.89, P<0.05). Compared with control group and empty vector group, the expression levels of ILK, p-Akt, and p-GSK-3β proteins in the HEC-1B cells in interference group were significantly reduced (P<0.05), and there were no statistically significant differences between the expression levels of Akt and GSK-3β proteins (P>0.05). The cell scratch test results showed that compared with control group and empty vector group, the migration distance of the HEC-1B cells in interference group was significantly shortened(P<0.05),and the number of invasion cells was significantly reduced (P<0.05). Conclusion: ILK is highly expressed in the endometrial carcinoma tissue, interfering the expression of ILK can reduce the migration and invasion abilities of endometrial carcinoma cells, and its mechanism may be related to the inhibition of phosphorylations of Akt and GSK-3β proteins.

Key words: integrin-linked kinase, endometrial carcinoma, cell migration, cell invasion

中图分类号:

R737.33

葛静, 谢磊, 李林, 魏旭静, 陈然, 王娜. 整合素连接激酶在子宫内膜癌组织中的表达及其对细胞迁移和侵袭能力的影响[J]. 吉林大学学报(医学版), 2020, 46(05): 1011-1015.

GE Jing, XIE Lei, LI Lin, WEI Xujing, CHEN Ran, WANG Na. Expression of integrin-linked kinase in endometrial carcinoma tissue and its effects on migration and invasion abilities of cells[J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 1011-1015.

参考文献

[1] DOCKERY L E, TANAKA T T, ZHANG R,et al. Incidence and implications of circulating tumor cells in endometrial cancer[J]. Gynecol Oncol, 2019, 154(1):24-27.
[2] POOKUNJU A P, AYYAPPAN S. Technique of laparoscopic hysterectomy and pelvic lymphadenectomy for endometrial cancer[J]. Indian J Surg Oncol, 2018, 9(2):290-293.
[3] 顾超, 李斌. 子宫内膜癌激素替代治疗[J]. 中国实用妇科与产科杂志, 2011, 27(11):823-825.
[4] COWAN M, STRAUSS J B, BARBER E L, et al. Updates on adjuvant chemotherapy and radiation therapy for endometrial cancer[J]. Curr Opin Obstet Gynecol, 2019, 31(1):31-37.
[5] DABI Y, U ZAN J, BENDIFALLAH S, et al. Prognostic value of local relapse for patients with endometrial cancer[J]. Eur J Surg Oncol, 2017, 43(11):2143-2149.
[6] 佐晶, 安菊生, 宋艳, 等. 子宫内膜癌淋巴结转移及临床病理因素与预后的相关性[J]. 基础医学与临床, 2016, 36(6):840-845.
[7] 邢雷, 庄翔, 陈俊霞. 核糖核酸酶抑制因子与整合素连接激酶相互作用通过ILK/AKT/mTOR通路抑制膀胱癌体内外生长[J]. 中国癌症杂志, 2018, 28(1):30-37.
[8] CHU P C, KULP S K, BEKAII-SAAB T, et al. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer[J]. Small Gtpases, 2018, 9(6):452-456.
[9] 李菁菁, 刘玉, 赵娟, 等. 过表达整合素连接激酶促进心脏c-Kit+细胞的存活和增殖[J]. 中国病理生理杂志, 2017, 33(9):1537-1543.
[10] O'MEARA R W, CUMMINGS S E, MICHALSKI J P, et al. A new in vitro mouse oligodendrocyte precursor cell migration assay reveals a role for integrin-linked kinase in cell motility[J]. BMC Neurosci, 2016, 17(1):7-22.
[11] MABETA P. 3P Anti-VEGF and integrin-linked kinase knockdown inhibit angiogenesis in vitro and suppress vascular tumor growth in vivo[J]. Ann Oncol, 2016, 27(9):573-575.
[12] QI F H, CAI P P, LIU X, et al. Adenovirus-mediated P311 ameliorates renal fibrosis through inhibition of epithelial-mesenchymal transition via TGF-β1-Smad-ILK pathway in unilateral ureteral obstruction rats[J]. Int J Mol Med, 2018, 41(5):3015-3023.
[13] 邓樑卿, 周龙书, 史文静. 整合素连接激酶在上皮性卵巢癌中的表达及其临床意义[J]. 实用医学杂志, 2013, 29(12):1953-1955.
[14] MAITY G, FAHREEN S, BANERJI A, et al. Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa)[J]. Mol Cell Biochem, 2010, 336(1/2):65-74.
[15] 李春玲, 刘春在, 李胜水, 等. ILK、ER在子宫内膜癌组织中的表达及相关性分析[J]. 中国当代医药, 2010, 17(9):39-41.
[16] 石雪萍, 李静, 冉建华, 等.人参皂苷Rh2调控PI3K/AKT/GSK-3β信号通路诱导人结肠癌细胞凋亡[J]. 中国药理学通报, 2017, 33(1):114-119.
[17] DEHGHANY A M, ABOEE M F, MORADI P. SiO2@antisense molecules covered by nepetalactone, extracted from Nepeta gloeocephala, inhibits ILK phosphorylation and downstream PKB/AKT signaling in HeLa cells[J]. Cancer Gene Ther, 2017, 24(1):28-32.
[18] 杨群, 李丽. 下调高迁移率族蛋白B1对宫颈癌细胞侵袭、迁移的影响及机制[J]. 山东医药, 2018, 58(26):27-30.
[19] 庄翔, 朱军, 吕梦欣, 等. 特异性ILK siRNA对膀胱癌EJ细胞EMT及移植瘤生长的影响[J]. 基础医学与临床, 2016, 36(2):191-198.
[20] SHIRLEY L A, MCCARTY S, YANG M C, et al. Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target[J]. Surgery, 2015, 159(1):163-170.